Please sign in to follow a disease.

Refractory diffuse large B-cell lymphoma (DLBCL)

Clinical trials for Refractory diffuse large B-cell lymphoma (DLBCL) explained in plain language.

Never miss a new study

Get alerted when new Refractory diffuse large B-cell lymphoma (DLBCL) trials appear

Sign up with your email to follow new studies for Refractory diffuse large B-cell lymphoma (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 3 Not yet recruiting 1 Not yet finished but already full! 2

Can a Faster-Dosed antibody drug paired with lenalidomide help lymphoma that came back after CAR T-Cell therapy?

Disease control Not yet recruiting

Researchers are testing a combination of two drugs, epcoritamab and lenalidomide, in adults whose large B-cell lymphoma has come back after CAR T-cell therapy. The trial enrolls about 55 people in France. Participants receive epcoritamab as a shot under the skin using a faster do…

Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control

Last updated Sep 12, 2026 00:00 UTC

Refractory diffuse large B-cell lymphoma (DLBCL)

Get alerted when new Refractory diffuse large B-cell lymphoma (DLBCL) trials appear

Can a Faster-Dosed antibody drug paired with lenalidomide help lymphoma that came back after CAR T-Cell therapy?